Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2014
03/25/2014CA2617099C Macrocyclic inhibitors of hepatitis c virus
03/25/2014CA2614070C Cathepsin cysteine protease inhibitors
03/25/2014CA2612403C Antiviral compounds and methods
03/25/2014CA2606783C Modulators of indoleamine 2,3-dioxygenase and methods of using the same
03/25/2014CA2604463C 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
03/25/2014CA2602231C Prevention of hiv-infection
03/25/2014CA2597447C Novel tubulin polymerisation inhibitors
03/25/2014CA2597395C Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
03/25/2014CA2594542C Synthesis of inhibitors of p90rsk
03/25/2014CA2594418C N-(heteroaryl)-1h-indole-2-carb0xamide derivatives and their use as vanilloid trpv1 receptor ligands
03/25/2014CA2591757C Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine
03/25/2014CA2585983C Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
03/25/2014CA2577982C Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
03/25/2014CA2574308C Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
03/25/2014CA2571377C Cyclic progestin regimens and kits
03/25/2014CA2565247C Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
03/25/2014CA2563699C Kinase modulators and method of use
03/25/2014CA2547020C 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
03/25/2014CA2531020C Cannabinoid receptor modulator
03/25/2014CA2527174C Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor
03/25/2014CA2524610C Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
03/25/2014CA2524094C Low sodium solution
03/25/2014CA2521149C Annatto extract compositions, including geranyl geraniols and methods of use
03/25/2014CA2507018C Materials and methods for preventing and treating microbe-mediated epithelial disorders
03/25/2014CA2494677C Derivatives of monosaccharides for drug discovery
03/25/2014CA2404448C Genes involved in intestinal inflammatory diseases and use thereof
03/25/2014CA2379891C Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity
03/25/2014CA2368369C Docetaxel in combination with rhumab her2 for the treatment of cancers
03/21/2014CA2812245A1 Method of inhibiting constitutively active phosphorylated flt3 kinase
03/20/2014WO2014043715A1 Compounds that modulate intracellular calcium
03/20/2014WO2014043707A1 Oligomer-containing benzamide-based compounds
03/20/2014WO2014043706A1 Method of synthesizing thyroid hormone analogs and polymorphs thereof
03/20/2014WO2014043686A2 Multi-encapsulated formulations made with oxidized cellulose
03/20/2014WO2014043685A1 Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof
03/20/2014WO2014043647A1 Therapeutic compositions and associated methods
03/20/2014WO2014043628A1 Genes associated with dasatinib sensitivity
03/20/2014WO2014043618A1 Process for preparing therapeutic nanoparticles
03/20/2014WO2014043576A1 Method of treatment or prophylaxis of infections of the eye
03/20/2014WO2014043446A1 Prodrugs of amino quinazoline kinase inhibitor
03/20/2014WO2014043442A1 Inhibition of viral infection-triggered asthma with c-kit inhibitor
03/20/2014WO2014043437A1 Amino-quinolines as kinase inhibitors
03/20/2014WO2014043433A1 Methods of improving long-term survival and reducing hospitalization readmission rates for subjects suffering from hepatic encephalopathy
03/20/2014WO2014043432A1 Methods of administering rifaximin for weight loss and treatment of obesity
03/20/2014WO2014043380A1 Novel nucleotide prodrug compounds and use
03/20/2014WO2014043376A1 Metalloenzyme inhibitor compounds
03/20/2014WO2014043368A1 Methods for increasing brain functionality using 2-fucosyl-lactose
03/20/2014WO2014043347A1 Mdr method and products for treating mrsa
03/20/2014WO2014043336A2 Tetrandrine pharmaceutical formulations and method
03/20/2014WO2014043330A1 Methods for modulating corticosterone levels in psychologically stressed individuals
03/20/2014WO2014043320A1 Methods of administering rifaximin without producing antibiotic resistance
03/20/2014WO2014043296A1 Aminoisoquinoline derivatives as protein kinase inhibitors
03/20/2014WO2014043292A1 Double-stranded oligonucleotide molecules to p53 and methods of use thereof
03/20/2014WO2014043265A1 Novel uses of neuraminidase inhibitors in infectious diseases
03/20/2014WO2014043257A1 Treatment for vitiligo
03/20/2014WO2014043246A1 Enoyl reductase inhibitors with antibacterial activity
03/20/2014WO2014043230A2 Formulations comprising idebenone, n-acetyl-s-farnesyl-l-cysteine and ergothioneine and uses thereof
03/20/2014WO2014043208A1 Formulations of enzalutamide
03/20/2014WO2014043144A1 Methods for treating inflammation and pain
03/20/2014WO2014043068A1 Glucosylceramide synthase inhibitors
03/20/2014WO2014043046A1 Treatment and prevention of p. aeruginosa infections using coformycin analogs
03/20/2014WO2014043019A1 Hiv protease inhibitors
03/20/2014WO2014042939A1 Ketone linked benzothiazole inhibitors of endothelial lipase
03/20/2014WO2014042924A1 Polycarbonates bearing pendant primary amines for medical applications
03/20/2014WO2014042688A1 Methods of producing molindone and its salts
03/20/2014WO2014042605A1 New tiotropium bromide crystalline form
03/20/2014WO2014042598A1 Drug therapy for cancer, including multiple myeloma
03/20/2014WO2014042501A1 Formulation for improving the quality of the meat of animals bred for consumption
03/20/2014WO2014042450A1 Targeted drug delivery system for poorly soluble drug
03/20/2014WO2014042448A1 Composition for preventing or treating liver diseases, containing phosphatidylcholine and biphenyl dimethyl dicarboxylate, and use thereof
03/20/2014WO2014042426A1 Composition comprising saikosaponin a, berberine, and licoisoflavone b for preventing or treating gastric diseases
03/20/2014WO2014042416A1 Oral composition containing dapoxetin-free base
03/20/2014WO2014042392A1 Composition using metformin for preventing or treating immune diseases including lupus
03/20/2014WO2014042325A1 Composition for preventing and treating inflammatory diseases and immune diseases, containing apo-9'-fucoxanthinone as active ingredient
03/20/2014WO2014042292A1 Composition comprising protein kinase c activator for promoting stem cell adhesion, and method for promoting stem cell adhesion
03/20/2014WO2014042263A1 Novel renin inhibitor
03/20/2014WO2014042261A1 Sirtuin gene potentiator, and pharmaceutical product, cosmetic product, and food product using same
03/20/2014WO2014042250A1 Drug-containing ultrafine fiber and utilization thereof
03/20/2014WO2014042238A1 Sulfonamide compound
03/20/2014WO2014042231A1 Crystal and pharmaceutical preparation containing the same crystal
03/20/2014WO2014042176A1 Method for producing fused-heterocyclic derivative, and production intermediate thereof
03/20/2014WO2014042043A1 Pharmaceutical composition containing luliconazole
03/20/2014WO2014041885A1 Cholecystokinin secretion-promoting composition
03/20/2014WO2014041846A1 Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
03/20/2014WO2014041825A1 Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation
03/20/2014WO2014041784A1 Ube2t peptides and vaccines containing the same
03/20/2014WO2014041708A1 Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
03/20/2014WO2014041563A1 Synergistic anti-cancer composition and a process for the preparation thereof
03/20/2014WO2014041551A1 Formulation comprising imatinib as oral solution
03/20/2014WO2014041518A1 Thienopyrrole derivatives as itk inhibitors
03/20/2014WO2014041485A1 Fast dissolving ocular insert
03/20/2014WO2014041425A1 Daptomycin formulations and uses thereof
03/20/2014WO2014041424A1 Histone deacetylase inhibitors for enhancing activity of antifungal agents
03/20/2014WO2014041393A1 Combination of compounds derived from gallic acid for the treatment of cancer
03/20/2014WO2014041362A1 Uv radiation cleavable compounds
03/20/2014WO2014041349A1 Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
03/20/2014WO2014041179A1 Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
03/20/2014WO2014041175A1 Novel inhibitor compounds of phosphodiesterase type 10a
03/20/2014WO2014041144A1 Crystalline compounds
03/20/2014WO2014041142A1 Tablet formulation of a phosphatidylinositol 3-kinase inhibitor
03/20/2014WO2014041141A1 Methods of inhibiting hair growth
1 ... 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 ... 7860